INVESTORS

Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.

 

About Us

Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Apr 20, 2021

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized...

Apr 12, 2021

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a...

Apr 6, 2021

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a full-service Contract Research...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons
  • SEC Filings
    View annual filings, quarterly filings and more
  • FAQ's
    Check out our frequently asked questions for more information
  • Events
    Upcoming and past investor related events and announcements
Investor Presentation

Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists.

Download

Subscribe
Keep up to date on Hoth Therapeutics News. Simply fill out your email below and you will be added to our email alerts.
* Required Fields
Our Pipeline

Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists.

Investor Contact

LR Advisors LLC

Email: investorrelations@hoththerapeutics.com

Phone: (678) 570-6791